Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
283 hedge funds and large institutions have $6.25B invested in Blueprint Medicines in 2024 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 102 increasing their positions, 89 reducing their positions, and 27 closing their positions.
93% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 27
34% more call options, than puts
Call options by funds: $134M | Put options by funds: $99.9M
15% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 89
9% more funds holding
Funds holding: 259 → 283 (+24)
4% more capital invested
Capital invested by funds: $6.02B → $6.25B (+$229M)
0.26% more ownership
Funds ownership: 107.34% → 107.6% (+0.26%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$70.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.4M |
| 3 |
Holocene Advisors
New York
|
+$61.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$33.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$110M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$51.1M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$32.9M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$22.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$19.9M |
BPMC Hedge Fund Activity: Q1 2024 in Review
283 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2024, worth a combined $6.25B — up 3.8% from $6.02B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new BPMC positions and 27 closed out — a net gain of 25 holders — while 102 added to existing stakes and 89 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $70.5M. The largest seller was Morgan Stanley, cutting an estimated $110M.
- 283 institutional investors held Blueprint Medicines (BPMC) as of Q1 2024, up from 259 in Q4 2023.
- Funds reported $6.25B of Blueprint Medicines stock for Q1 2024, up 3.8% quarter-over-quarter.
- 52 funds opened new Blueprint Medicines positions in Q1 2024 and 27 closed out, a net change of +25 holders.
- The largest Blueprint Medicines buyer in Q1 2024 was T. Rowe Price Associates, an estimated $70.5M added.
- The largest Blueprint Medicines seller in Q1 2024 was Morgan Stanley, an estimated $110M sold.
Based on aggregated 13F filings for Q1 2024.